摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1,1-dimethylethyl 6-hydroxy-1,2,4,5-tetrahydro-3H-3-benzazepine-3-carboxylate | 873446-59-4

中文名称
——
中文别名
——
英文名称
1,1-dimethylethyl 6-hydroxy-1,2,4,5-tetrahydro-3H-3-benzazepine-3-carboxylate
英文别名
2-methyl-2-propanyl 6-hydroxy-1,2,4,5-tetrahydro-3H-3-benzazepine-3-carboxylate;tert-butyl 6-hydroxy-1,2,4,5-tetrahydro-3H-benzo[d]azepine-3-carboxylate;tert-butyl 6-hydroxy-1,2,4,5-tetrahydro-3-benzazepine-3-carboxylate
1,1-dimethylethyl 6-hydroxy-1,2,4,5-tetrahydro-3H-3-benzazepine-3-carboxylate化学式
CAS
873446-59-4
化学式
C15H21NO3
mdl
——
分子量
263.337
InChiKey
DAJYPAOLINAEGA-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.7
  • 重原子数:
    19
  • 可旋转键数:
    2
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.53
  • 拓扑面积:
    49.8
  • 氢给体数:
    1
  • 氢受体数:
    3

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • [EN] OXADIAZOLE DERIVATIVES ACTIVE ON SPHINGOSINE-1-PHOSPHATE (SIP)<br/>[FR] DÉRIVÉS D'OXADIAZOLE ACTIFS SUR LA SPHINGOSINE-1-PHOSPHATE (S1P)
    申请人:GLAXO GROUP LTD
    公开号:WO2009080725A1
    公开(公告)日:2009-07-02
    The present application discloses oxadiazole based compounds of Formula (I) active on sphingosine-1-phosphate (S1P) in particular useful to treat lupus erythematosus. A is phenyl or a 5 or 6-membered heteroaryl ring; R1 is up to two substituents independently selected from halogen, C(1-3)aIkoxy, C(1-3)flyoroalkyl, cyano, optionally substituted phenyl. C(1-3)fluoroalkoxy. C(1-6)alkyl and C(3-6)Cyctoalkyl; R2 is hydrogen, halogen or C(1-4)alkyl; B is a 7 membered saturated ring selected from the following: Formulae (a) (b) (c) R3 is hydrogen or (CH2)1-4MCO2H; R4 is hydrogen or C(1-3)alkyl optionally interrupted by oxygen;
    本申请披露了一种基于噁二唑的化合物,其化学式为(I),对神经酰胺-1-磷脂酸(S1P)具有活性,特别适用于治疗红斑狼疮。其中,A为苯基或5或6元杂环芳基环;R1为最多两个取代基,可独立选择自卤素、C(1-3)烷氧基、C(1-3)氟烷基、氰基、可选择取代的苯基、C(1-3)氟烷氧基、C(1-6)烷基和C(3-6)环烷基;R2为氢、卤素或C(1-4)烷基;B为以下选项中的7元饱和环之一:(a)(b)(c);R3为氢或(CH2)1-4MCO2H;R4为氢或C(1-3)烷基,可由氧原子中断。
  • COMPOUNDS
    申请人:HEER Jag Paul
    公开号:US20100174065A1
    公开(公告)日:2010-07-08
    The present invention relates to novel oxadiazole derivatives having pharmacological activity, processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of various disorders.
    本发明涉及具有药理活性的新型噁二唑衍生物,其制备方法,含有它们的药物组合物以及它们在治疗各种疾病中的用途。
  • Compounds Having Affinity For the Dopamine D3 Receptor and Uses Thereof in Medicine
    申请人:Bonanomi Giorgio
    公开号:US20080269195A1
    公开(公告)日:2008-10-30
    Compounds of formula (I) or a salt thereof are disclosed: wherein, A, m R 1 , R 2 , R 3 , q, W 1 , W 2 , R 4 and R 5 are as defined in the description. Processes for preparation and uses of the compounds in medicine, for example for the treatment of schizophrenia or drug dependency, are also disclosed.
    公开了化学式(I)的化合物或其盐:其中,A,m,R1,R2,R3,q,W1,W2,R4和R5如描述中所定义。还公开了制备这些化合物的过程以及在医学上使用这些化合物的用途,例如用于治疗精神分裂症或药物依赖症。
  • 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS
    申请人:Allen John Gordon
    公开号:US20090099155A1
    公开(公告)日:2009-04-16
    The present invention provides 6-substituted 2,3,4,5-tetrahydro-1H-benzoazepines of Formula I as selective 5-HT 2C receptor agonists for the treatment of 5-HT 2C associated disorders including obesity, obsessive/compulsive disorder, depression, and anxiety: where: R 6 is -C≡C-R 10 , -O-R 12 , -S-R 14 , or -NR 24 R 25 ; and other substituents are as defined in the specification.
    本发明提供了式I的6-取代的2,3,4,5-四氢-1H-苯并氮烯作为选择性5-HT2C受体激动剂,用于治疗5-HT2C相关疾病,包括肥胖症、强迫症、抑郁症和焦虑症:其中:R6为-C≡C-R10,-O-R12,-S-R14或-NR24R25;其他取代基如规范中所定义。
  • 6 Substituted 2, 3,4,5 Tetrahydro-1H-Benzo[d]Azepines as 5-HT2c Receptor Agonist
    申请人:ALLEN JOHN GORDON
    公开号:US20120028961A1
    公开(公告)日:2012-02-02
    The present invention provides 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines of Formula I as selective 5-HT 2C receptor agonists for the treatment of 5-HT 2C associated disorders including obesity, obsessive/compulsive disorder, depression, and anxiety: where: R 6 is —S—R 14 ; and other substituents are as defined in the specification.
    本发明提供了公式I的6-取代的2,3,4,5-四氢-1H-苯并[d]氮杂环作为选择性5-HT2C受体激动剂,用于治疗5-HT2C相关疾病,包括肥胖症、强迫症、抑郁症和焦虑症:其中:R6为—S—R14;其他取代基如规范中所定义。
查看更多